Medindia

X

Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting

Friday, April 4, 2008 General News J E 4
Advertisement
SUNNYVALE, Calif., April 3, 2008 Pharmacyclics,Inc. (Nasdaq: PCYC) today announced multiple presentations on its noveloncology and autoimmune disease drug candidates at the American Associationfor Cancer Research (AACR) 2008 Annual Meeting being held April 12-16, 2008,at the San Diego Convention Center in San Diego, CA.

Several presentations relate to the company's histone deacetylase(HDAC)inhibitor, which is now in a multicenter Phase 1 clinical trial, and the useof proprietary biomarkers to predict drug sensitivity. An additionalpresentation describes the activity of an HDAC-8 selective inhibitor that hasdemonstrated anti-inflammatory properties in preclinical studies.

"Our strong presence at the AACR meeting highlights the breadth of ourproduct portfolio in cancer and autoimmune diseases," said Richard A. Miller,M.D., president and chief executive officer of Pharmacyclics. "In addition todata on our HDAC inhibitor, other presentations describe our Factor VIIa andBtk inhibitors, which we anticipate will enter clinical testing later thisyear."

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative productsto treat cancer and other serious diseases. The company is leveraging itssmall-molecule drug development expertise to build a pipeline in oncology andother diseases based on a wide range of targets, pathways and mechanisms. Moreinformation about the company, its technology, and products can be found athttp://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R)are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made inthis press release about enrollment and future plans for our clinical trials,progress of and reports of results from preclinical and clinical studies,clinical development plans and product development and corporate partneringactivities are forward-looking statements, as defined in the PrivateSecurities Litigation Reform Act of 1995. The words "project," "believe,""will," "may," "continue," "plan," "expect," "intend," "anticipate,"variations of such words, and similar expressions also identifyforward-looking statements, but their absence does not mean that the statementis not forward-looking. The forward-looking statements are not guarantees offuture performance and are subject to risks and uncertainties that may causeactual results to differ materially from those in the forward-lookingstatements. Factors that could affect actual results include risks associatedwith our ability to estimate accurately the amount of cash to be used to fundoperations over the next 12 months, our ability to obtain future financing andfund the product development of our pipeline; the initiation, timing, design,enrollment and cost of clinical trials and preclinical studies; unexpecteddelays in clinical trials and preclinical studies and the timing for makingrelated regulatory filings; our ability to establish successful partnershipsand collaborations with third parties; the regulatory approval process in theUnited States and other countries; our future capital requirements; and thefact that data from preclinical studies and Phase 1 or Phase 2 clinical trialsmay not necessarily be indicative of future clinical trial results. Forfurther information about these risks and other factors that may affect theactual results achieved by Pharmacyclics, please see the company's reports asfiled with the U.S. Securities and Exchange Commission from time to time,including but not limited to its annual report on Form 10-K for the periodended June 30, 2007 and its subsequently filed quarterly reports on Form 10-Q.Forward-looking statements contained in this announcement are made as of thisdate, and we undertake no obligation to publicly update any forward-lookingstatement, whether as a result of new information, future events or otherwise.The presen
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Iomai and Merck & Co., Inc. Evaluate Use of Iomai ...
S
Telecommunications Carriers Respond To Congress' D...